Metabolic Plasticity in Pancreatic Cancer: The Mitochondrial Connection

Overview

Journal Mol Metab

Specialty Cell Biology

Date 2024 Dec 30

PMID 39736443

Authors

Noemi Ghiglione

Damiano Abbo

Anastasia Bushunova

Andrea Costamagna

Paolo Ettore Porporato

Miriam Martini

Affiliations

Soon will be listed here.

Abstract

Background: Cellular metabolism plays a pivotal role in the development and progression of pancreatic ductal adenocarcinoma (PDAC), with dysregulated metabolic pathways contributing to tumorigenesis and therapeutic resistance. Distinct metabolic heterogeneity in pancreatic cancer significantly impacts patient prognosis, as variations in metabolic profiles influence tumor behavior and treatment responses.

Scope Of The Review: This review explores the intricate interplay between mitochondrial dynamics, mitophagy, and cellular metabolism in PDAC. We discuss the significance of mitophagy dysregulation in PDAC pathogenesis, emphasizing its influence on treatment responses and prognosis. Furthermore, we analyze the impact of mitochondrial dynamics alterations, including fission and fusion processes, on PDAC progression and tumorigenesis.

Major Conclusion: Targeting mitochondrial metabolism holds promise for advancing PDAC therapeutics. Ongoing clinical trials underscore the therapeutic potential of modulating key regulators of mitochondrial dynamics and mitophagy. Despite inherent challenges, these approaches offer diverse strategies to enhance treatment efficacy and improve patient outcomes.

References

Zhu X, Chudnovskiy A, Baudrier L, Prizer B, Liu Y, Ostendorf B . Functional Genomics In Vivo Reveal Metabolic Dependencies of Pancreatic Cancer Cells. Cell Metab. 2020; 33(1):211-221.e6. PMC: 7790894. DOI: 10.1016/j.cmet.2020.10.017. View

Ferretti G, Quaas C, Bertolini I, Zuccotti A, Saatci O, Kashatus J . HSP70-mediated mitochondrial dynamics and autophagy represent a novel vulnerability in pancreatic cancer. Cell Death Differ. 2024; 31(7):881-896. PMC: 11239841. DOI: 10.1038/s41418-024-01310-9. View

Yang S, Hwang S, Kim M, Seo S, Lee J, Jeong S . Mitochondrial glutamine metabolism via GOT2 supports pancreatic cancer growth through senescence inhibition. Cell Death Dis. 2018; 9(2):55. PMC: 5833441. DOI: 10.1038/s41419-017-0089-1. View

Li W, Wilson G, Bachmann M, Wang J, Mattarei A, Paradisi C . Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunocompetent Orthotopic Murine Model. Cancers (Basel). 2022; 14(11). PMC: 9179813. DOI: 10.3390/cancers14112618. View

Zhao C, He R, Shen M, Zhu F, Wang M, Liu Y . PINK1/Parkin-Mediated Mitophagy Regulation by Reactive Oxygen Species Alleviates Rocaglamide A-Induced Apoptosis in Pancreatic Cancer Cells. Front Pharmacol. 2019; 10:968. PMC: 6735223. DOI: 10.3389/fphar.2019.00968. View

Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sanchez N, Marchesini M . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514(7524):628-32. PMC: 4376130. DOI: 10.1038/nature13611. View

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

Lin Z, Lin X, Chen J, Huang G, Chen T, Zheng L . Mitofusin-2 is a novel anti-angiogenic factor in pancreatic cancer. J Gastrointest Oncol. 2021; 12(2):484-495. PMC: 8107624. DOI: 10.21037/jgo-21-176. View

Davidson S, Jonas O, Keibler M, Hou H, Luengo A, Mayers J . Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat Med. 2016; 23(2):235-241. PMC: 5407288. DOI: 10.1038/nm.4256. View

10.

Liang J, Yang Y, Bai L, Li F, Li E . DRP1 upregulation promotes pancreatic cancer growth and metastasis through increased aerobic glycolysis. J Gastroenterol Hepatol. 2019; 35(5):885-895. DOI: 10.1111/jgh.14912. View

11.

Hollinshead K, Parker S, Eapen V, Encarnacion-Rosado J, Sohn A, Oncu T . Respiratory Supercomplexes Promote Mitochondrial Efficiency and Growth in Severely Hypoxic Pancreatic Cancer. Cell Rep. 2020; 33(1):108231. PMC: 7573785. DOI: 10.1016/j.celrep.2020.108231. View

12.

Biancur D, Paulo J, Malachowska B, Del Rey M, Sousa C, Wang X . Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun. 2017; 8:15965. PMC: 5500878. DOI: 10.1038/ncomms15965. View

13.

Sousa C, Biancur D, Wang X, Halbrook C, Sherman M, Zhang L . Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016; 536(7617):479-83. PMC: 5228623. DOI: 10.1038/nature19084. View

14.

Mukhopadhyay S, Encarnacion-Rosado J, Lin E, Sohn A, Zhang H, Mancias J . Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer. Sci Adv. 2023; 9(16):eadf9284. PMC: 10115412. DOI: 10.1126/sciadv.adf9284. View

15.

Picca A, Faitg J, Auwerx J, Ferrucci L, DAmico D . Mitophagy in human health, ageing and disease. Nat Metab. 2023; 5(12):2047-2061. DOI: 10.1038/s42255-023-00930-8. View

16.

Carmona-Carmona C, Dalla Pozza E, Ambrosini G, Errico A, Dando I . Divergent Roles of Mitochondria Dynamics in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2022; 14(9). PMC: 9105422. DOI: 10.3390/cancers14092155. View

17.

Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier C . PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol. 2010; 189(2):211-21. PMC: 2856912. DOI: 10.1083/jcb.200910140. View

18.

Guardado Rivas M, Stuart S, Thach D, Dahan M, Shorr R, Zachar Z . Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613. PLoS One. 2022; 17(6):e0269620. PMC: 9176802. DOI: 10.1371/journal.pone.0269620. View

19.

Spinelli J, Haigis M . The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol. 2018; 20(7):745-754. PMC: 6541229. DOI: 10.1038/s41556-018-0124-1. View

20.

Bielcikova Z, Stursa J, Krizova L, Dong L, Spacek J, Hlousek S . Mitochondrially targeted tamoxifen in patients with metastatic solid tumours: an open-label, phase I/Ib single-centre trial. EClinicalMedicine. 2023; 57:101873. PMC: 10102891. DOI: 10.1016/j.eclinm.2023.101873. View